Saniona, a leading biotech company within ion-channel research, today announces that it shall receive a milestone payment of USD $0.75 million in relation to achievement of a specific research milestone under its drug discovery and development collaboration with Pfizer Inc.

“Saniona aims to bring ion channel discoveries to Pharma partners and drug discovery expertise for the potential development of innovative treatment options in important disease areas like neurology,” said Jørgen Drejer Ph.D., CEO of Saniona.

Saniona and Pfizer entered into a drug discovery and development collaboration in the beginning of 2014. The collaboration focuses on research of potential medicines to treat neurological disorders based on one of Saniona’s unique research programs. Pfizer has exclusive worldwide rights to research, develop, manufacture and commercialize any potential medicines identified through the collaboration.

Under the terms of the agreement, Saniona is eligible to receive additional milestone payments upon the achievement of additional research and development milestones as well as royalties on any potential products developed and commercialized by Pfizer as a result of this collaboration. The total potential value of the upfront and research and development milestone payments is up to USD $51.75 million of which Saniona, following the payment of USD $0.75 million, has received USD $2.25 million.

“Through this collaboration we are supporting one of our business objectives of financing a part of the company’s research efforts by collaboration agreements with pharmaceutical companies. A research and development collaboration such as this with Pfizer, a leading pharmaceutical company, complements our internal proprietary product development efforts utilizing our unique ion channel platform,” said Jørgen Drejer Ph.D., CEO of Saniona.

For more information please contact
Jørgen Drejer, CEO, Saniona, Mobile: +45 2028 9705, E-mail: [email protected]

About Saniona
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with major pharmaceutical companies including Janssen Pharmaceuticals Inc. and Pfizer Inc., as well as Saniona’s Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Idec Inc. Saniona is based in Copenhagen, Denmark, where it has a research centre of high international standard and 18 employees. Saniona is listed at AktieTorget since April 2014 and has about 1000 shareholders. The company’s share is traded under the ticker SANION. Read more at www.saniona.com.

Saniona AB, Baltorpvej 154, DK-2750 Ballerup, Denmark
Web: saniona.com Email: [email protected]